借鉴加拿大经验构建英国韧性高血压控制体系:CHEP 项目启示
Building a resilient system to improve blood pressure control in the UK: lessons from our Canadian cousins
加拿大高血压教育计划(CHEP)通过整合指南、社区筛查及多学科协作,推动血压控制率从1992年的13.2%升至2013年峰值69.9%,随后因访问基础设施脆弱而回落。该案例表明,系统性服务传递优于单纯药物更新,为英国当前38%的控制率困境提供了重构访问路径的蓝图。
Introduction
Hypertension remains the leading modifiable cardiovascular risk factor worldwide, yet blood pressure (BP) control rates vary widely across otherwise comparable health jurisdictions [1]. Given that practitioners have access to identical BP lowering drugs and draw from the same evidence base, outcomes are clearly determined less by pharmacology than by the organisation and delivery of care. No country illustrates this more clearly than Canada, where a dramatic rise and subsequent fall in BP control rates offers a unique natural experiment to learn from.
At their peak in 2012-13, BP control rates in Canada were approaching 69.9% of treated patients with hypertension, a rate unmatched by any comparable healthcare systems, and one the UK, currently at 38%, has never achieved [2, 3]. Neither access to novel drug classes nor an unusually adherent population can fully explain this success rate. Rather, this appears to have been the result of a deliberate, systematically implemented infrastructure whose foundations were laid by the Canadian Hypertension Education Program (CHEP), designed to embed up-to-date guidelines directly into primary care practice. But since 2014 Canadian control rates have declined [2]. The drugs stayed the same. The guidelines kept coming. But patients weren’t getting through the door.
The successes and failures of the Canadian model provide a unique blueprint for the UK. Canada has shown us that population scale BP control is achievable within a publicly funded system, using existing drug classes. By ensuring the infrastructure to convert consultation into prescriptions and patient follow-up is facilitated, the system simply works. But we now know this infrastructure is fragile. With our own struggles in the UK now mirroring those in Canada, both systems are drifting further from what Canada proved was possible. This essay argues that the priority should not be new antihypertensive classes, revised thresholds or better guidelines, but the deliberate reconstruction of the access infrastructure that turns evidence into action.
You’ve got a way
Canada’s rise to becoming a global trailblazer in BP control did not happen by accident. In 1999, CHEP was launched with the unconventional mandate to go beyond mere recommendations and produce guidelines that reached the consultation room [4]. It recognised that producing annually updated, evidence-based recommendations was necessary but insufficient to improve hypertension management. What followed was the evolution of a model integrating every level of Canadian society that set it apart globally.
The programme was built around three distinct task forces. The Recommendations Task Force developed a standardised, evidence-based guideline process requiring majority support from a committee of over fifty multidisciplinary experts. The Implementation Task Force drew from members across medicine, pharmacy, nursing and exercise physiology, tailoring messages and materials to ensure recommendations were adopted across every possible route into clinical practice [5]. The Outcomes Task Force continuously monitored real-world impact, looking beyond survey data and delving into electronic health records and provincial economic data [6]. Together they created a closed loop system of implementation, measurement and revision with outcomes data feeding back into the annual cycle [7]. The programme could correct itself far more dynamically, moving closer to the current NICE surveillance model rather than waiting the 5-7 years typical of guideline cycles in the US and Europe [8, 9].
The real innovation however was the horizontal reach across Canadian society. CHEP did not work in isolation. With direct involvement from the Heart and Stroke Foundation of Canada, College of Family Physicians, hypertension and specialist societies, CHEP had the combined weight of these organisations behind it along with, most critically, the government [10]. This coalition created the credibility, cross-disciplinary buy-in, and sustained investment needed to ensure implementation was not just an idea.
Results followed. BP control rose from 13.2% in 1992 to 64.6% in 2007 before hitting the 69.9% peak in 2013 [11]. This equates to a more than five-fold improvement over two decades, whilst, the rest of the world trailed behind. A well-oiled machine in motion rather than a pharmacological revolution, it was entirely reproducible because it had been deliberately designed.
I’m gonna getcha good
Hypertension cannot be treated if it is not diagnosed. Access to a primary care provider is the pivotal moment in the BP control pathway, without which no guideline however well designed, reaches the patient. It is no coincidence that Canada’s rise in BP control was accompanied by a complementary surge in hypertension diagnoses, with prevalence having doubled from 1994 reaching 22.6% in 2013. The impact was huge, resulting in a reduction in mortality rates of patients with hypertension from 9.4 to 7.9 deaths per 1000 [12]. Access was not a background condition for success, rather it was the active ingredient converting guidelines into outcomes.
By harnessing the cross-disciplinary coalition embedded within the programme, CHEP mobilised Canadians within their own communities to get cuffs on arms. Cardiovascular Health Awareness Programs (CHAPs) were funded across Canada, empowering pharmacists and trained volunteers to raise awareness, conduct initial BP assessments, and pass results directly to GPs [10, 13]. Rather than waiting for a patient to present at the clinic, a moment often arriving too late and too infrequently, diagnosis was actively pursued in community settings [14]. Waiting rooms were replaced with pharmacies, community halls and workplaces as a deliberate move to reduce the time between elevated BP and clinical diagnosis.
Following this success, the treatment adjustment timeline became a top priority. Community pharmacists were empowered to titrate antihypertensives without the need for a GP appointment for every adjustment. Sustaining that control was pursued with equal rigour; guidelines mandated treated patients be reviewed monthly until two consecutive visits confirmed BP control [15, 16]. Patients were also encouraged to keep in contact with their GP during treatment. Home BP monitoring reinforced this with half of Canadians living with hypertension owning a validated home monitor at their peak control period, embedding BP awareness into daily life [17]. Multiple contact points spread responsibility for boosting awareness, diagnosis and control across the system. This coupling of infrastructure and access now in full flow, supported across medicine, pharma, public and government; BP control in Canada seemed secured.
That don’t impress me much
Progress, however, began to plateau in the intervening years before entering a sharp decline. Control rates struggled to hold above 60% until 2019 before collapsing to 42.7% by 2022-24, the lowest reported level in two decades [18]. This represented a near 30% loss from Canada’s historic peak, erasing a generation of progress. The timing and events surrounding this breakdown serve to isolate the key structures that were required to make the system work. The model was not sustained by the content of its recommendations, rather by the infrastructure ensuring their implementation.
The 2010s saw the slow erosion of the primary mechanisms used to pursue BP control. Critically, governmental support fell, weakening both the financial and logistical support for the infrastructure required [17]. CHEP was reorganised into Hypertension Canada, which removed primary-care organisations from formal oversight, diminishing the direct connection to the clinic. Implementation and outcome task forces were rolled back, along with the annual review process, effectively reverting the organisation back to simply producing guidelines [17, 19]. Recommendations kept coming but the machinery to push them into practice was being quietly dismantled.
To compound this, Canada’s primary care workforce began contracting, mirroring the ongoing crisis in the UK. By 2023 more than one in six Canadian adults had no regular primary care provider with only 26% being able to obtain a same or next-day appointment, and the average number of patients seen per GP had fallen from 1746 in 2013 to 1353 by 2021 [20, 21]. Meanwhile in the UK, the number of GP practices fell by 20% between 2013 and 2023, with patient lists growing by 40% and 14% fewer GPs per patient than in 2015 [22]. With the former winning infrastructure rolled back and access declining, Canada is finding its BP control nearly on par with the UK.
Ultimately, Canada built something that worked, then defunded and dismantled the very parts that facilitated success, to observe the rapid deterioration of the enviable outcomes achieved. The story demonstrates that a system can be constructed but without sustained commitment to its infrastructure, guidelines become documents and outcomes speak for themselves. The Canadian model will be ineffective in the UK without strategic and sustained investment in key areas.
Come on over
The ingredients for a Canadian-style system already exist in the UK, they just have not yet been assembled and set in motion. Crucially, the task ahead is not to import the model wholesale, but rather build upon current practice, identify what is missing, and commit to the infrastructure that connects the parts.
Canada’s early success depended on cross-sector buy-in. CHEP was more than a small team of specialists; it brought together hypertension experts, GPs, pharmacists, nurses, charitable foundations, and governmental stakeholders in a coordinated programme. This breadth gave CHEP authority, credibility and political weight to secure infrastructure required to begin population scale implementation. The UK, with comparable organisations such as the BIHS, BHF, RCGP and NICE, are poised to position themselves as a united implementation coalition. The combined influence of these bodies should be utilised to map a tailored plan for UK BP control, and begin the process to lobby for the resources required to make community awareness and detection routine.
A key aspect of the Canadian system was the prioritisation of public engagement. Patient-facing education, awareness campaigns and annual themes actively encouraged the public to know their numbers. By encouraging, normalising and embedding monitoring behaviour, patients are empowered to prioritise the pursuit of BP control between clinical contact points. With the wide availability of validated devices endorsed by NICE, the UK has the tools but lacks the scaled programme to support a structured pathway for patients for escalation and follow-up. Again, highlighting the difference between a recommendation and an implementation system.
The NHS Community Pharmacy BP Check Service and Pharmacy First initiatives already allow community pharmacists to conduct opportunistic BP checks, offer ambulatory monitoring and refer patients to their GP. Predicted to save ten million appointments annually, the infrastructure to ease pressure on GPs is also already in motion, with only some refinement required [23]. By extending prescribing rights to trained pharmacists for primary hypertension, allowing independent titration of treatment, an impactful element of the community model could be readily replicated.
Beyond implementation, the UK holds an advantage Canada cannot easily replicate. Resources such as the UK Biobank position the UK at the frontier of the next generation of hypertension insights. Research is beginning to elucidate pharmacogenomic determinants of antihypertensive drug response, supporting a move toward genetically informed treatment selection [24]. Alongside emerging evidence that genomic insights may also inform dietary interventions, the UK has the potential to deploy tailored strategies across lifestyle, diet and pharmacotherapy, not only emulating Canada’s success but extending it through precision care [25].
Finally, outcome reporting must be prioritised to regularly publish regional control rates, though this serves more than just progress tracking. By transparently disseminating results, a level of accountability is introduced to the bodies involved, it creates more data to feed continuous improvement and it has been suggested it can improve clinical engagement and morale [17]. The Quality and Outcomes Framework already provides a mechanism for this and could be utilised to produce a published national audit, replicating the success of the Outcomes Task Force.
Giddy Up!
Canada’s unparalleled success cannot be attributed to new discoveries in the field of hypertension. They outperformed because they built a system that enabled timely, reliable management and treatment at scale. With robust systems in place, control rates eclipsed that of the UK. But when systems weakened, outcomes followed suit, all against a common backdrop of evidence, drugs and guidance. The lesson is clear; BP control relies on delivery, not documents.
For the UK, the components to commence construction of a world-class model to convert diagnosis into sustained control already exist. If the professional bodies, societies, charities and government can commit to the long-term collaboration and investment, the present isolated initiatives can be moulded into a functional system. Canada has shown what is possible and, in its decline, what is fragile. Replication is feasible, but only if the structures recognise that access, infrastructure and collaboration are not optional, but essential.
References
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223–37.
Leung AA, Williams JVA, Padwal RS, McAlister FA. Prevalence, patient awareness, treatment, and control of hypertension in canadian adults with common comorbidities. CJC Open. 2024;6:1099–107.
Tapela N, Collister J, Clifton L, Turnbull I, Rahimi K, Hunter DJ. Prevalence and determinants of hypertension control among almost 100 000 treated adults in the UK. Open Heart. 2021;8:e001461.
Hemmelgarn BR, Chen G, Walker R, McAlister FA, Quan H, Tu K, et al. Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006. Can J Cardiol. 2008;24:507–12.
Drouin D, Campbell NR, Kaczorowski J. Implementation of recommendations on hypertension: the Canadian hypertension education program. Can J Cardiol. 2006;22:595–8.
Campbell NR, Onysko J. The outcomes research task force and the Canadian hypertension education program. Can J Cardiol. 2006;22:556–8.
Campbell NR, Chen G. Canadian efforts to prevent and control hypertension. Can J Cardiol. 2010;26:14C–17C.
Zeniodi ME, Tsaganos T, Menti A, Komnianou A, Kollias A, Stambolliu E. European hypertension guidelines: similarities and what the practicing physician should keep in mind. J Clin Med. 2026;15:859.
NICE guideline. Hypertension in adults: diagnosis and management. 2026 https://www.nice.org.uk/guidance/ng136.
Schiffrin EL, Campbell NRC, Feldman RD, Kaczorowski J, Lewanczuk R, Padwal R, et al. Hypertension in Canada: past, present, and future. Ann Glob Health. 2016;82:288–99.
McAlister FA, Feldman RD, Wyard K, Brant R, Campbell NRC, for the CHEP Outcomes Research Task Force. The impact of the Canadian hypertension education programme in its first decade. Eur Heart J. 2009;30:1434–9.
Padwal RS, Bienek A, McAlister FA, Campbell NRC. Epidemiology of hypertension in Canada: an update. Can Med Assoc J. 2016;32:687–94.
Kaczorowski J, Chambers LW, Dolovich L, Paterson JM, Karwalajtys T, Gierman T et al. Improving cardiovascular health at population level: 39 community cluster randomised trial of Cardiovascular Health Awareness Program (CHAP). 2011. https://doi.org/10.1136/bmj.d442.
Lu Y, Brush JE, Kim C, Liu Y, Xin X, Huang C, et al. Delayed hypertension diagnosis and its association with cardiovascular treatment and outcomes. JAMA Netw Open. 2025;8:e2520498.
Houle SKD, Padwal R, Tsuyuki RT. The 2012-3 Canadian hypertension education program (CHEP) guidelines for pharmacists. Can Pharm J (Ott). 2013;146:146–50.
Tsuyuki RT, Houle SKD, Charrois TL, Kolber MR, Rosenthal MM, Lewanczuk R, et al. Randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community. Circulation. 2015;132:93–100.
Campbell NR, Padwal R, Tsuyuki RT, Leung AA, Bell A, Kaczorowski J, et al. Ups and downs of hypertension control in Canada: critical factors and lessons learned. Rev Panam Salud Publica. 2022;46:e141.
McAlister FA, Bushnik T, Leung AA. Changes in hypertension prevalence and control in Canada after the COVID-19 pandemic: insights from the Canadian health measures survey cycle 7. Can J Cardol 2026. https://doi.org/10.1016/j.cjca.2026.04.013.
Leung AA, Bell A, Tsuyuki RT, Campbell NRC. Refocusing on hypertension control in Canada. Can Med Assoc J. 2021;193:E854–E855.
Rudoler D, Peterson S, Stock D, Taylor C, Wilton D, Blackie D, et al. Changes over time in patient visits and continuity of care among graduating cohorts of family physicians in 4 Canadian provinces. Can Med Assoc J. 2022;194:E1639–E1646.
Najafizada M. Beyond headcount: four dimensions of Canada’s primary care access crisis and a three-level agenda for action. Front Med (Lausanne). 2025;12:1695409.
Pettigrew L, Petersen I, Mays N, Cromwell D. The changing shape of English general practice: a retrospective longitudinal study using national datasets describing trends in organisational structure, workforce and recorded appointments. BMJ Open. 2024;14:e081535. https://doi.org/10.1136/bmjopen-2023-081535
Department of Health and Social Care. Pharmacy First: what you need to know. 2024. https://healthmedia.blog.gov.uk/2024/02/01/pharmacy-first-what-you-need-to-know/ (accessed 30 Apr2026).
Danielli M, Benfield N, Warren HR, Munroe PB. The future of pharmacogenomics in cardiovascular medicine. Pharmacogenomics J 2026; 0: 1–14.
Amenyah SD, Ward M, McMahon A, Deane J, McNulty H, Hughes C, et al. DNA methylation of hypertension-related genes and effect of riboflavin supplementation in adults stratified by genotype for the MTHFR C677T polymorphism. Int J Cardiol. 2021;322:233–239.
Acknowledgements
I would like to thank the 2026 Stanley Peart Essay Judges for their expert review of this manuscript: Professor Peter Sever, Professor Ian B. Wilkinson, Dr Luca Faconti, Dr Helen Warren and Dr Ryan McNally.
Funding
SM is funded by a Department for the Economy (Northern Ireland) Postgraduate Studentship.
Author information
Authors and Affiliations
Centre for Genomic Medicine, Biomedical Sciences Research Institute, Ulster University, Coleraine, Northern Ireland, UK
Steven W. Mitchell
British and Irish Hypertension Society Early Career Researchers Special Interest Group, London, UK
Steven W. Mitchell
Authors
- Steven W. Mitchell
Contributions
Steven W. Mitchell wrote the manuscript.
Corresponding author
Correspondence to Steven W. Mitchell.
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Ethical approval
Ethical approval was not required for this work as it did not involve any human or animal studies.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Mitchell, S.W. Building a resilient system to improve blood pressure control in the UK: lessons from our Canadian cousins. J Hum Hypertens (2026). https://doi.org/10.1038/s41371-026-01231-9
Received: 26 August 2026
Revised: 07 September 2026
Accepted: 15 September 2026
Published: 13 October 2026
Version of record: 13 October 2026
DOI: https://doi.org/10.1038/s41371-026-01231-9
来源:Nature 健康护理主题 · nature.com